352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Veracyte reported second-quarter 2024 total revenue of $114.4 million, up 27% from $90.3 million a year earlier, and swung to net income of $5.7 million from a net loss of $8.4 million. The company raised its full-year 2024 total revenue guidance to $432 million to $438 million from $402 million to $410 million, which is a positive signal for shareholders.
Q2 2024 total revenue was $114.4 million, up 27% from $90.3 million in Q2 2023; testing revenue rose 31% to $107.0 million.
Net income was $5.7 million, or $0.07 per diluted share, versus a net loss of $8.4 million, or $(0.12) per share, in Q2 2023.
Adjusted EBITDA was $24.0 million, or 21% of revenue, compared with $11.0 million, or 12% of revenue, a year earlier.
Full-year 2024 total revenue guidance rose to $432 million to $438 million; year-end cash guidance rose to $260 million to $270 million.
Progyny reported second-quarter 2024 revenue of $304.1 million, up 8.8%, with net income of $16.5 million and Adjusted EBITDA of $54.5 million, up 15%. The company said revenue per utilizing member is running below its expectations and revised its second-half outlook, now projecting full-year 2024 revenue of $1.165 billion to $1.20 billion. The board also authorized an additional $100 million share repurchase, which matters to shareholders because the outlook is softer even as profit and buybacks grew.
Q2 2024 revenue was $304.1 million, up 8.8%, and net income was $16.5 million, or $0.17 per diluted share, versus $0.15 a year earlier
Adjusted EBITDA was $54.5 million, up 15%, with an Adjusted EBITDA margin of 17.9%
Full-year 2024 revenue is now projected at $1.165 billion to $1.20 billion; third-quarter revenue is projected at $290.0 million to $303.0 million
On August 5, 2024, the board authorized an additional $100 million of share repurchases, after the company bought 5,593,128 shares for $159.8 million in the second quarter
TG Therapeutics reported second-quarter 2024 total revenue of $73.5 million, up from $16.1 million a year earlier, and net income of $6.9 million compared with a net loss of $47.6 million in the same period of 2023. The company raised its full-year 2024 U.S. BRIUMVI net revenue target to $290 million to $300 million from $270 million to $290 million, and authorized a share buyback of up to $100 million funded by a new $250 million term loan that repaid its Hercules debt.
Q2 2024 total revenue was $73.5 million versus $16.1 million in Q2 2023; diluted EPS was $0.04 versus $(0.34).
Full-year 2024 U.S. BRIUMVI net revenue target raised to $290 million to $300 million from $270 million to $290 million.
$250 million term loan with Blue Owl Capital and HealthCare Royalty matures August 2, 2029; proceeds repaid Hercules debt, and the Board authorized up to $100 million in share repurchases.
Audit Committee concluded a 2021 stock-grant expense error reflects a material weakness in internal control as of December 31, 2023; a 10-K/A will follow, and the company states there are no financial changes to the 2023 annual report.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.